 |
 |
 |
| January 17,2002 |
Combination Cold Remedy with Precision-Targeted Effectiveness Contains Triple Set of Special Ingredients  Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) will launch sales of Pabron Ace Tablet, a combination cold remedy, on February 1. This new self-medication product shows outstanding effectiveness against the four symptoms that are most distressing when people have colds. Pabron Ace Tablet targets four hard-to-bear cold symptoms-sore throat, cough, fever, and runny or stuffy nose-with a triple set of special ingredients: bromohexine hydrochloride, ibuprofen, and lysozyme chloride. In clinical trials, Pabron Ace Tablet proved remarkably effective, with a 98.6% overall improvement rate among cold sufferers. Since Taisho Pharmaceutical's launch of Pabron cough medicine in 1927, the company has continually expanded the Pabron line, developing new products and reformulating them to meet consumers' needs for combination cold remedy. Pabron Ace Tablet is a result of that ongoing drive to relieve the suffering caused by the common cold. It targets the four symptoms that respondents in a questionnaire study of 1,000 persons who had taken cold remedies listed most often as "particularly distressing symptoms I would like to clear up immediately." Pabron Ace Tablet is thus a combination cold remedy that meets the growing consumer demand for such products, demand that has risen with the spread of self-medication. Principal Product Features
Product Specifications
|
| Indications | For the relief of cold symptoms (Sore throat, cough, fever, runny nose, stuffy nose, sneezing, postnasal drip, headache, chills, joint pain) |
| Dosage | For persons 15 years of age and over, three doses of three tablets each per day |
| Date of release | February 1, 2002 (30-tablet size) March 4, 2002 (45-tablet size) |
| Expected sales | 3.0 billion yen in the first year (shipment basis, total for both package sizes) |
